Rejected from JACC? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024 and BioxBio; ACC/Elsevier, AHA, JAMA Network, ESC/Oxford journal pages and guides for authors (accessed June 2026). APCs are list prices excluding tax and may be reduced at submission.

1. JACC: Cardiovascular Interventions. The natural landing spot when the work is fundamentally interventional, coronary, structural, or peripheral, and the flagship's priority bar was about general-audience breadth rather than quality. The in-family transfer carries your files and often the reviews, which removes the scope-mismatch risk that sinks cold cross-journal moves.

2. JACC: Cardiovascular Imaging. If the real contribution is a multimodality imaging method or an imaging-driven clinical finding, this specialty title frames it far better than the flagship. Pick it when the imaging, not a broad practice change, is the protagonist.

3. JACC: Heart Failure. The cleanest specialist home for heart-failure pathophysiology, diagnosis, therapy, or trial work that is too subfield-specific for the flagship's general readership but genuinely advances heart-failure care.

4. Circulation. Reach here only when the contribution is a top-tier general cardiovascular advance, a major trial or a mechanistic result with broad reach. Its priority bar is at least as high as JACC's, so it suits work the JACC editors called "sound but not quite high enough priority," not work they called too narrow.

5. European Heart Journal. The ESC flagship and the strongest non-US general-cardiology alternative at the top tier. A good move when the work has international or European clinical relevance and you want a general-cardiology audience comparable to JACC's.

6. JAMA Cardiology. Best for a concise, tightly framed clinical study where the practice implication is clear and the manuscript can carry a sharp, decision-focused message. It rewards economy and a clean clinical takeaway over comprehensive mechanism.

7. American Heart Journal. The better fit when the manuscript is solid broad cardiovascular practice that did not clear the top-tier priority bar, including study designs, methods papers, and negative trials it explicitly welcomes. Lower IF, lower priority bar, real readership. For a concise international general-cardiology home below the very top tier, Heart (BMJ, IF ~2.9) is the closest peer to this slot.

JACC runs an in-family transfer within the JACC family of specialty journals, and a rejecting JACC editor can offer a one-click transfer that carries your manuscript files, and often the reviewer reports, to a more suitable subfield title. The matching uses editor recommendations: an interventional paper is routed toward JACC: Cardiovascular Interventions, an imaging paper toward JACC: Cardiovascular Imaging, a heart-failure paper toward JACC: Heart Failure.

You can accept, decline, or ignore the offer and submit manually anywhere. A transfer offer is a routing suggestion, not a quality endorsement, so treat the destination as you would any other target.

Practical ladder by rejection reason:

• Desk-rejected for low priority but sound and general? This is the classic step-down or lateral case. Try Circulation or European Heart Journal if the work is genuinely top-tier general cardiology; otherwise step to JAMA Cardiology, American Heart Journal, or Heart. Do not assume a JACC priority rejection means the science is weak.

• Desk-rejected because the work is too narrow or subfield-specific? This is the textbook in-family transfer case.

Accept a JACC specialty-title offer (Interventions, Imaging, or Heart Failure) if the suggested journal matches the subfield. The specialty bar rewards exactly the depth the flagship called too narrow.

• Rejected after review for generalizability, a single-center base, or an underpowered endpoint? Fix it before resubmitting anywhere. Every serious cardiology venue will raise the same point. Carry the strengthened clinical-significance argument and any added analysis into the transfer or the manual resubmission.

In our pre-submission review work with JACC manuscripts, the rejections we see most often cluster into four named rejection patterns. Each maps to a JACC editorial triage pattern, and each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere. In our review of JACC submissions, these four account for the large majority of the desk decisions authors find hardest to predict.

The practice-changing abstract on single-center evidence. Across our JACC pre-submission reviews, the single most common desk trigger is an abstract that promises a practice-changing finding while the Results rest on a single-center cohort, a registry slice, or a subgroup that was not powered for the headline claim.

JACC's editors decide on priority for a broad cardiology audience, so a strong claim that generalizes from one institution invites the question they ask first: would a cardiologist elsewhere change practice on this evidence? Tighten the abstract to the claim the data actually support, add the multicenter or external-validation context if you have it, and the priority calculus shifts. Without that, the desk screen reads the gap between the abstract and the cohort as overreach.

This is testable: read your abstract's strongest sentence and ask whether your sample size and study design license it.

Incremental confirmation framed as a new advance. A second recurring pattern in the JACC manuscripts we review is a sound study that mostly confirms a well-established effect, framed in the introduction and discussion as a novel contribution. The editorial question at this journal is not "is this correct?" but "is this important enough for a 5-percent-acceptance general journal?" Reviewers and editors consistently flag the gap between a confirmatory result and a novelty claim.

The fix is either an honest reframing toward the genuinely new element (a new population, a new mechanism, a new clinical decision it informs) or a move to a specialty or broad-practice journal where incremental confirmation is in scope.

An endpoint that does not answer a clinical decision. We see manuscripts where the primary endpoint is a surrogate, a composite that buries the clinically meaningful component, or a statistical-significance result with an effect size too small to change management. JACC weighs utility: does this help a clinician decide something?

JACC editors explicitly screen for whether the result changes care, so when the endpoint and the effect size do not map onto a clinical decision, the priority drops regardless of methodological cleanliness. Check that your primary endpoint, its effect size, and its confidence interval together support an actual change in care, and that your statistical analysis matches the trial design.

Subfield depth with no general-cardiology through-line. The fourth pattern is a technically excellent paper aimed at one subspecialty (a specific imaging sequence, a niche device, a narrow electrophysiology question) with no framing for the general reader. The flagship's scope is breadth; the same manuscript is often a strong fit for a JACC specialty title. When the manuscript's true center of gravity is one subfield, the desk filter routes it out fast, regardless of quality.

Read your own introduction and ask: is there a clear through-line to a decision a general cardiologist makes, or is this written only for the subfield? If it is subfield-only, the right move is a specialty journal, not a flagship resubmission.

Don't just resubmit the same file down the ladder. The fastest way to collect a second rejection is to send an unrevised manuscript to a journal that screens for the same thing JACC did, and some manuscripts need real work, not a faster next submission. A desk rejection for priority or scope is a routing problem you can fix by choosing the right journal and reframing for its readership.

A post-review rejection for limited generalizability, a single-center base, or an endpoint that does not change care is a substance problem, and the same concerns will reappear at any serious cardiology venue. Be honest about which one you got.

Two cases call for real work before resubmitting, not a faster next submission. First, if reviewers questioned whether the result generalizes beyond your center or your subgroup, the manuscript needs external context, multicenter data, or an honestly narrowed claim. Second, if the endpoint or effect size was challenged, new analysis (and sometimes a reframed primary outcome) is the only fix.

Appealing is rarely worth it: a priority or generalizability rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean resubmission to a better-fit journal.